- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Total Funding
- $48.0M
- Last Round
- $30.0M Extension RoundDec 2025
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Proviva Therapeutics is a clinical-stage biotechnology company founded in 2019 and headquartered in Boston, Massachusetts, pioneering novel immuno-cytokine therapeutics for cancer treatment. The company's proprietary pro-cytokine fusion protein platform engineers conditionally active cytokines that remain dormant in healthy tissue and activate selectively in the tumor microenvironment, improving therapeutic window. Its lead program PTX-912 is a first-in-class PD-1 antibody–IL-2 pro-drug fusion protein currently in Phase 1 clinical trials for locally advanced and metastatic solid tumors. Proviva is backed by OrbiMed and Viva BioInnovator.
Summary
Proviva Therapeutics is a Biotech company based in Boston, United States, founded in 2019. It has raised $48.0M in total across 2 rounds, most recently a $30.0M Extension Round in Dec 2025. Investors include OrbiMed, Longpan Investment and Hankang Capital.
Funding History
Dec 2025
Sign up to see all 2 events
Funding: Series A through Extension Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/proviva-therapeutics"><img src="https://indexed.vc/api/badge/company/proviva-therapeutics" alt="Proviva Therapeutics on Indexed.vc" width="260" height="76" /></a>